After one extradural injection of 0.25 % bupivacaine 0.3 ml and 3 H-bupivacaine 0.005 mCi in multilamellar liposomes, no systemic radioactivity (plasma, liver, heart muscle) was obtained for 1 h, and the labelling was less than that of systemic distribution of plain bupivacaine for the following 3 h. In contrast, radioactivity in the lumbar spinal nerves peaked in the first hour and remained higher than that of plain bupivacaine for 4 h. No radioactivity was measured in cerebrospinal fluid. Small unilamellar vesicles incorporating 3 H-cholesterol did not significantly label spinal nerves and central nervous structures indicating that the mode of action of liposomal bupivacaine did not involve uptake by nerve structures. Rapid uptake of radioactivity by spinal nerves suggested exchange of bupivacaine between liposomes and nerve sheaths. (Br.
Previous animal studies have suggested that multilamellar liposomes (MLV) remain in a depot after extradural administration [1, 2] . Bupivacaine in an MLV vehicle was associated with low, constant and prolonged plasma concentrations of drug after extradural administration [1] ; Extradural administration of MLV-associated 0.5 % bupivacaine to humans was associated with prolonged analgesia after surgery without motor block [3] . Extradural injection of liposomal 0.25 % bupivacaine produced prolongation of pain relief without motor block in one patient suffering chronic cancer pain [4] .
In this study we have examined the relationship between the clinical effects of the liposomal local anaesthetic and the extradural depot of its vehicle. Drug distribution into plasma, myocardium, liver, cerebrospinal fluid (CSF), lumbar spinal nerves and medulla was compared after injection of plain or liposomal bupivacaine into the rabbit extradural space. The local relationships of the liposomes with the lumbar spinal nerves, the medulla and brain tissues were examined by administering small unilamellar vesicles (SUV) in which 3 H-cholesterol was added to the cholesterol component.
Materials and methods
Egg phosphatidylcholine (EPC T 12063-1, Lipoid K.G., Ludwigshafen, Germany) and cholesterol (Merck, Darmstadt, Germany) were the raw materials of the liposome formulations. Bupivacaine HCl was obtained from the Office Chimique (Brainel'Alleud, Belgium). Sodium chloride, hydrochloric acid, acetic acid, sulphuric acid, sodium hypochlorite, sodium hydroxide, monosodium dihydrogenophosphate, dipotassium hydrogenophosphate, all of analytical grade, were obtained from Merck. Organic solvents were dichloromethane, chloroform, methanol and ethanol (Merck). Phosphate-buffered saline (PBS), pH8.l, 285 mosmol kg Ϫ1 H2O, comprised NaH2PO4 11.5 mg, K2HPO4 0.36 mg and NaCl 0.68 mg in 1 ml of water for injection. 3 H-Bupivacaine 1 mCi ml Ϫ1 (Institut des RadioEléments, Fleurus, Belgium) in ethanol solution was used as the marker of the local anaesthetic. The molecule was radiolabelled on the methyl group of the hydrophobic xylidine moeity. 3 H-Cholesterol 1 mCi ml Ϫ1 (Amersham, Ghent, Belgium) was used as the membrane marker of the SUV bilayer. Suspensions of MLV and blood samples were spun using a bench centrifuge (Cryofuge 6-4, Heraeus Christ GMBH, Osterode, Germany). Preparation of SUV from MLV was performed by sonication using a Soniprep 150 Ultrasonic Disintegrator (MSE, Crawley, UK). Sephadex G25M (PD10 columns, Pharmacia LKB, Uppsala, Sweden) and Sepharose 4B (Pharmacia LKB) were used for separation of SUV from free bupivacaine. Radiolabelled liposomes and radioactive plasma were dissolved in a tissue solubilizer (Soluene 350, Packard, Meriden, USA). Radioactivity was counted in a liquid scintillation cocktail (Instafluor, Packard). A scintillation spectrophotometer (Rackbeta Liquid Scintillation Counter, Pharmacia LKB) was used for tritium radioactive counting.
The size of the MLV was measured with a Coulter LS-130 particle size analyser based on laser diffraction. Electron microscopy was performed with a Jeol 100 SX transmission electron microscope.
Chemical quality controls of the MLV comprised ammonium thiocyanate (Merck), hexahydrated ferric chloride (Merck), butylhydroxytoluene (Janssen Pharmaceutica, Beerse, Belgium), glycine (Merck), thiobarbituric acid (Aldrich Chemie, Milwaukee, WI, USA), tetrahydroxypropane (Merck), lysophosphatidylcholine (Sigma, St Louis, MO, USA) and Merck 16485 silica-coated TLC plates. Bupivacaine and phospholipids were titrated using a Gilford spectrophotometer (Gilson Response Spectrometer, USA).
We used New Zealand albino rabbits, weighing approximately 2.5 kg, purchased from the Rechtpersoonlijkheid Rijksstation (Ghent, Belgium). The animals were anaesthetized and sedated with Hypnorm (fluanisone and fentanyl, Janssen Pharmaceutica). Epicranial and 24-gauge needles were obtained from Terumo (Zellik, Belgium). Animals were killed with phenobarbitone (Nembutal, Abbott).
ASSOCIATION OF BUPIVACAINE WITH MLV
Bupivacaine was associated with liposomes made of EPC and cholesterol, as described previously [5] . Bupivacaine was dissolved in water and precipitated at pH 11 with NaOH 0.1 mol litre
Ϫ1
. Apolar bupivacaine was obtained by filtration and desiccation. Apolar bupivacaine dichloromethane solution was mixed homogeneously in a glass vial with EPC and cholesterol dissolved in the same organic solvent in a molar ratio 4 : 3. H-Bupivacaine in ethanol solution was added. Evaporating the solvent in nitrogen resulted in the formation of a dry lipid film made of EPC, cholesterol, lipophilic bupivacaine and its radionuclide. This film was kept overnight in a vacuum lyophilizer in order to remove the last traces of dichloromethane. PBS 1 ml, pH 8.1, was added to the lipid film, and MLV were formed by vortexing until the film disappeared completely. After 1 h at room temperature, a liposomal pellet was separated from the supernatant by centrifugation at 3500 g for l0 min. After five successive rinsings, bupivacaine 2.5 mg and 
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Quality controls of the liposomal bupivacaine formulations were performed following the recommendations of Barenholz and Amselem [6] and Betageri, Jenkins and Parsons [7] for preparations of liposomal drugs for human use. These quality controls focused on morphology, size of the liposomes associated with the local anaesthetic and chemical integrity and dose of bupivacaine and phospholipids. All quality control assays were performed on liposome-associated 0.25 % bupivacaine without radionuclide.
Phospholipid vesicles were observed by freezeetching electron microscopy [8] . Liposomal droplets were frozen by direct immersion in liquid Freon 22 and maintained in liquid nitrogen (Ϫ196 °C). After introducing the frozen blocks into the vacuum chamber at Ϫ150 °C (Balzers BAF 400 freezeetching unit), they were cracked with a knife blade. Sublimation of water (freeze-drying) was produced for 1 min at Ϫ100 °C. The etched faces were converted into replicates after platinum shadowing (45°, 8 s) and carbon coating. The specimens were dissolved away through H2O, H2SO4 and sodium hypochlorite. Replicates were viewed in a transmission electron microscope.
The sizes of the MLV were measured using a Coulter LS-130 particle size analyser based on laser diffraction of light scattered from particles exposed to a collimated light beam. Auto-rinsing of the particle size analyser was performed with PBS 3 litre and the run cycle was performed with 3-ml liposomal preparations. All operations were computerized, including statistics. This vesicle-sizing method is currently applied to liposomes [9] . Results were analysed following the recommendations of Ruf, Georgalis and Grell [10] and Hauser [8] .
The chemical integrity of the bupivacaine molecule associated with MLV was determined by infrared (IR) and ultraviolet (UV) spectroscopy using the spectra provided by the manufacturer and by the pharmacopeia as references. Bupivacaine was extracted from liposomes by acidification and then measured by UV spectrophotometry. A sample of the liposomal suspension (1.5 ml) was poured into a test tube of 5 ml and centrifuged at 3500 g for 10 min at 4 °C. The supernatant (1 ml) was diluted by 1 ml of HCl 0.2 mol litre ) were tested as controls. A direct method based on the complex formed between the phosphate group of the phospholipids and ammonium ferrothiocyanate [11] has been used routinely for phospholipid titration. This complex was extracted into chloroform and determined spectroscopically. This method was very rapid and sensitive from 10 to 100 nmol [12] . To a sample of liposomal suspension containing not more than 50 g of phospholipids in buffer were successively added chloroform 1 ml and 2 ml of a solution of hexahydrated ferric chloride 0.1 mol litre Ϫ1 and ammonium thiocyanate 0.4 mol litre
Ϫ1
, followed by chloroform 1 ml. This mixture was vortexed for at least 2 min. After 5 min of centrifugation at 2000 g, 4 °C, the supernatant was discarded and the optical density of the chloroform lower phase was measured at a wavelength of 470 nm. The concentration of phospholipids was calculated in comparison with standard solutions of EPC from 1 to l00 g ml
.
Lipid peroxides were estimated as thiobarbituric acid reactive material (TBARM) by the thiobarbituric acid test [13] . The accuracy of the method was limited to TBARM 2 nmol [14] . To 0.1 ml of the solution to be assayed were added 0.1 ml of hexahydrated ferric chloride solution 0.01 mol litre Ϫ1 , 0.1 ml of a butylhydroxytoluene solution in ethanol as antioxidant 0.01 mol litre Ϫ1 , 1.5 ml of glycine buffer 0.3 mol litre Ϫ1 (pH 3.6) and 1.5 ml of 0.5 % thiobarbituric acid in a 0.3 % sodium dodecyl sulphate solution in water. The mixture was vortexed and heated for 15 min in a boiling water bath. After cooling in an ice bath, glacial acetic acid 1 ml and chloroform 2 ml were added. The tube was vortexed for 15 s and centrifuged for 10 min at 2000 g, 4 °C. The optical density of the chloroform phase was measured at a wavelength of 532 nm. The amount of TBARM was determined in comparison with a standard solution of tetrahydroxypropane hydrolysed under the same conditions. Results were reported as nmol TBARM in the phospholipid suspension.
Semi-quantitative determination of neurotoxic lysophosphatidylcholine was carried out by thin layer chromatography (TLC) [6] . The solution tested was extracted by the method described by Bligh and Dyer [15] with some modifications. To 0.1 ml of the solution to be tested were added methanol 0.1 ml and chloroform 0.1 ml. The mixture was vortexed for 15 s and centrifuged for 10 min at 2000 g, 4 °C. The supernatant was discarded and a 0.01-ml spot of the lower chloroform phase was settled on the baseline of a 10-cm, silica-coated TLC plate. The eluent system was a mixture of chloroform-methanol-water in a volume ratio of 65/25/4. After development, the plate was revealed by exposure to iodine vapours. Retention factors (Rf) of EPC and lysophosphatidylcholine were determined with a standard solution in chloroform. It appeared by chromatography of successive dilutions that the lowest amount of lysophosphatidylcholine to be detected was 5 g ml . The extradural space was identified by loss of resistance to air and all solutions administered did not exceed 0.5 ml.
One extradural injection of a 0.3-ml solution containing 0.25 % bupivacaine 2.5 mg ml Ϫ1 and 3 Hbupivacaine 0.005 mCi ml Ϫ1 was performed at the sacral level (S2-3). Bupivacaine was either in the native hydrochloride form (pH 6.5) or associated with the liposomal preparations (MLV 20 mg ml Ϫ1 , pH 8.l) described above. No animal died from cardiotoxic effects.
The radioactivity plasma level was determined by counting arterial blood. A 24-gauge needle was inserted into the ear artery. Blood (2 ml) was withdrawn into heparinized tubes at various times after extradural injection over the following 4 h. The blood samples were centrifuged at 3500 g for 15 min. Plasma samples of 0.5 ml were mixed with Soluene 1 ml in Packard glass vials, Instafluor 10 ml was added, and beta counting was performed after 1 night at 4 °C.
The plasma level of radioactivity, expressed as a percentage of the injected dose (% ID) in the total plasma of the animal, was calculated as follows: (cpm in 1 ml plasma total cpm injected Ϫ1 ) 32.8 2.5 100 ϭ % ID in plasma, considering a rabbit plasma volume of 32.8 ml kg Ϫ1 [16] . The method was sensitive from 0.01 % ml Ϫ1 and was reproducible (SD Ͻ 5 % of the mean value for 10 measurements of the same sample) from 0.05 to 10 % ml
. BIODISTRIBUTION OF PLAIN AND LIPOSOME-ASSOCIATED BUPIVACAINE Animals (n ϭ 6 at each experimental time) were killed from 15 min to 4 h by i.v. administration of phenobarbitone 5 ml. Before killing, CSF 0.5-1 ml was collected by suboccipital puncture at the level of the cisterna magna. Immediately after death, the vertebral arches were opened dorsally and lumbosacral spinal nerves were dissected. Three samples were rinsed repeatedly in NaCl 150 mmol litre Ϫ1 , blotted arid weighed. They were dissolved for 48 h at 37 °C in Soluene 1 ml. The abdominal cavity and the thoracic wall were incised. The liver and heart were removed, rinsed in NaCl 150 mmol litre
, blotted and weighed. Three samples of each organ weighing approximately 1 g and CSF 0.1 ml were dissolved in Soluene 1 ml and counted in Instafluor 10 ml. After correction for quenching, results were expressed in reference to the ID (% ID) incorporated in CSF 1 ml, in the whole organ (liver, heart) or in 1 g of tissue (spinal nerves). The method was sensitive from cpm countings corresponding to 0.02 % ID g Five animals were killed 15, 30, 60, 180 and 240 min after extradural injection. Before sacrifice, CSF 0.5Ϫ1 ml was collected by suboccipital puncture at the level of the cisterna magna. The spinal cord was opened by section of the vertebral arches from the cervical to the sacral level. The spinal cord was dissected in thoracic and lumbar sections. The cauda equina, the meninges and several lumbar spinal nerves were isolated. After opening of the skull, the brain was dissected and three samples weighing approximately 1 g were obtained. Before beta count-ing, CSF 0.1 ml and nerve tissues were diluted in tissue Soluene 1 ml and Instafluor 10 ml. The results were expressed as the % ID in 1 g of tissue or 1 ml of CSF.
STATISTICAL ANALYSIS
Results are expressed as mean (SD). Statistical significance was determined using the one-way ANOVA test with repeated measurements and unpaired Student's t test for comparison between the two groups. P Ͻ 0.05 was considered statistically significant. Table 1 summarizes the physical and chemical characteristics of five different preparations of liposome-associated 0.25 % bupivacaine. The chemical integrity of the local anaesthetic molecules associated with MLV was proved by IV and IR spectrometry. The UV spectrograms obtained with bupivacaine extracted from liposomes were identical to the reference spectrum found in the pharmacopeia and to the spectra from acid solutions of bupivacaine and apolar bupivacaine. Absorption occurred at 270.5 nm and the molar extinction coefficient was 338 ml mg Ϫ1 cm
Results

Ϫ1
. The IR spectrogram was identical to the reference spectrum of the pharmacopeia. Liposomal EPC injected into the rabbits' extradural spaces did not present any detectable neurotoxic lysophosphatidylcholine or cytotoxic peroxides using methods recommended for human trials [6, 7] . Laser Coulter statistics showed that the polydispersity of the drug carriers was broader than that of the stannous oxinate MLV used for scintigraphic biodistribution studies [2] (table 2 ). An electron micrograph of MLV-associated bupivacaine confirmed the multilamellarity and, dispersity of the vesicles.
The kinetic profile of plasma radioactivity from 15 min to 4 h after extradural administration of bupivacaine and bupivacaine-MLV (BP-MLV) is shown in figure 1 . Radioactivity was not observed in plasma during the first 30 min after injection of BP-MLV while it peaked at 1.65 % ID at the same time as when using plain bupivacaine. The plasma concentration of drug originating from liposomes increased to 0.5 % ID after 1 h and remained constant during the next 3 h ( fig. 1 ). Hepatic radioactivity averaged 10 % ID after 30 min and increased to 20 % ID 4 h after extradural injection in the BP group. There was no radioactivity in the liver in the first 30 min when using liposomeassociated bupivacaine. Hepatic accumulation increased slowly to 7.5 % over 2 h and did not change after 4 h ( fig. 2) . Similar results were obtained in myocardium.
Radioactive labelling of the lumbosacral spinal nerves averaged 1 % ID g Ϫ1 during the first hour after injection of plain bupivacaine. During the same period, radioactive accumulation from BP-MLV averaged 15 % ID g
. Spinal nerves labelling decreased respectively to 0.1 and 2 % ID g Ϫ1 (P Ͻ 0.01) after 4 h in both experimental conditions ( fig. 3) .
Radioactivity counted in the lumbar spinal cord peaked at 7 % ID g Ϫ1 , 15 min after administration of plain bupivacaine. It decreased after 30-60 min, and almost no labelling was present after 2 and 4 h (fig.  4) . In contrast, radioactivity increased slowly for 30 min after extradural administration of the liposomal aminoamide, remained at this level for 1 h and subsequently declined to values corresponding to those found after injection of plain local anaesthetic (fig. 4 ). These results demonstrate the inverse relationship between labelling in spinal nerves and lumbar medulla with two formulations of bupivacaine (table 3) . There was no radioactivity in CSF for 4 h after injection of liposomal bupivacaine (table  4) .
Radioactivity in the brain, thoracic and lumbar spinal cord, lumbar spinal nerves, cauda equina and meninges after extradural injection of 3 Hcholesterol-labelled SUV was less than the limit of sensitivity of the method.
Discussion
The quality controls showed that the association of bupivacaine with MLV did not alter its molecular integrity, as observed by UV and IR spectrometry. Bupivacaine was seen as crystals inserted into and outside the MLV. The range of size of the liposome drug vehicles was greater than that of stannous . Each experimental point represents the mean, SD, of six rabbits. P Ͻ 0.001 between the two groups for experimental points at 15 min using Student's t test; P Ͻ 0.001 between values at 30 and 60 min in the plain bupivacaine group; P Ͻ 0.01 between 60 and 120 min in the same group; in the BP-MLV group, P Ͻ 0.01 between 60 and 120 min using ANOVA test. oxinate MLV used for scintigraphic study [2] . This indicates that the extradural depot of liposomes may be extrapolated to MLV-associated bupivacaine.
The association of bupivacaine with MLV altered the blood and tissue distribution profiles of the drug after extradural injection. As described previously [1] , the systemic concentrations (plasma, liver, myocardium) of bupivacaine were lower for 4 h compared with those after administration of an equal dose of plain drug. In contrast, the concentration of bupivacaine was 10-15 times higher in the lumbosacral spinal nerves for 4 h after extradural administration of BP-MLV. The labelling of brain, the thoracic and lumbar spinal cord, lumbar spinal nerves, cauda equina and meninges after extradural injection of 3 H-cholesterol-labelled SUV was at the inferior limit of detection of radioactivity counting. The pharmacokinetic studies were conducted for 4 h because human postoperative pain relief after extradural injection of MLV-associated 0.25 % bupivacaine is approximately 4-5 h [17] .
There was no systemic labelling for the 30-60 min after extradural injection of liposome-associated bupivacaine and during this time spinal nerve concentrations reached a peak. Subsequently, systemic labelling increased while local nerve tissue radioactivity decreased. This behaviour may be explained by the properties of liposomes vehiculating drugs.
Phospholipid vesicles are known to release their drug content in a slow and controlled manner [7] . This may account for the delay in vascular absorption from the extradural MLV depot leading to delayed plasma, myocardial and hepatic radioactivity. The systemic toxicity of bupivacaine is associated with its plasma concentration [18, 19] . The low and constant plasma concentrations of the drug with BP-MLV suggests a reduction in systemic toxicity.
Uptake by local nerve structures may be explained in terms of the relationships of liposomes with the phospholipid bilayers of the nerve sheaths and of the nerve cell membranes. The hypothesis of fusion between the phospholipid bilayers of the liposomes and the cell membranes is now largely considered as a low level process [20] . The difficulty in obtaining liposome fusion with cell membranes in vivo has been noted [21] . The cell fusion hypothesis has been largely replaced by the concept of endocytosis [7, 20, 21] . This mode of action suggests that target cells are endowed with phagocytic properties. However, this is not the case for the nerve sheaths of the spinal nerves. Liposomes cannot cross the epineurium and endoneurium and this was confirmed by the absence of radioactivity from 3 H-cholesterol-labelled SUV (diameter 0.05 m) in all nerve structures. In addition, this absence of radioactivity allows us to discard the hypothesis of fusion of the liposomes with the nerve sheath phospholipid bilayers. The SUV used in our study are known to undergo both the greatest degree of phagocytosis and also the highest probability of cell fusion [7, 20] .
It has been shown that liposomes labelled by a pyrenyle radical could transfer almost immediately their marker to the cell membrane by exchange between the two phospholipid bilayers [22] . Such an immediate transfer of bupivacaine between the liposomes and extradural spinal nerve sheaths would establish a concentration of bupivacaine inside the nerve membranes sufficient to ensure rapid analgesic effect of the drug without active accumulation at the level of the inner motor C-fibres. This would account for the rapid onset and prolonged sensory block without motor block observed in post-surgical analgesia [3] .
The reasons why the drug released from the liposomes did not cross the subarachnoid membrane are not clear. The absence of bupivacaine in the CSF after administration of liposome-associated local anaesthetic should be reinvestigated using liquid or gas chromatography. This is important as it has been reported that diffusion of bupivacaine into the spinal cord via the CSF would play an important part in the motor block produced by local anaesthetics administered extradurally [23] . The lack of this phenomenon with BP-MLV may explain the absence of motor block observed in clinical trials [2] .
The plasma and tissue measurements of bupivacaine were based on 3 H-bupivacaine radioactivity counting. Tritium was chosen because it is a stable isotope with a half-life of 12 yr. Bupivacaine is catabolized rapidly into more polar compounds by the liver. The radioactivity measured in the rabbit plasma thus included bupivacaine and catabolic products and did not represent true local anaesthetic concentrations. Tritium labelling of bupivacaine was performed on a methyl group associated with the benzoyl lipophilic moiety of the molecule and hepatic biotransformation of the local anaesthetic does not change this part of the molecule. The main purpose of the present study was limited to a comparison of tissue distributions of bupivacaine using the two formulations, plain and liposome-associated. The feasibility of a stable isotope method has been demonstrated in similar experiments [24] . However, qualitative chromatographic detection of bupivacaine and known metabolites is required to clarify these issues.
